Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals — OIS Glaucoma Innovation Summit 2021

16 slides from Aerie Pharmaceuticals's conference presentation, Oct 21, 2021

  1. Slide 1: Building a Global Netarsudil Franchise

    Building a Global Netarsudil Franchise Tom Mitro President and COO OIS Glaucoma Innovation Summit – October 21, 2021 Summary July 2021 Exhibit 99.1

  2. Slide 2: Important Information

    Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety

  3. Slide 3: Netarsudil Franchise Growth in the U.S.

    Netarsudil Franchise Growth in the U.S.

  4. Slide 4: U.S. Glaucoma Market - ~$3B Market, 34M TRx, 55M bottles

    U.S. Glaucoma Market - ~$3B Market, 34M TRx, 55M bottles Rhopressa® launched 2018 Rocklatan® launched 2019 2020 U.S. Glaucoma Market Graph Source: IQVIA 2020 CAI: Carbonic Anhydrase Inhibitor AA: Alpha Agonist BB: Beta Blocker OIS Glaucoma Innovation Showcase October 2021

  5. Slide 5: Netarsudil Franchise Snapshot – U.S.

    Monthly prescribers = ~10,000 Weekly prescribers = ~5,000 Rhopressa® and Rocklatan® are covered for 8 out of 10 insured patients (Commercial and Med D) >215,000 PAs submitted for Rhopressa® and Rocklatan® Netarsudil Franchise Snapshot – U.S. OIS Glaucoma Innovation Showcase October 2021

  6. Slide 6: Monthly Franchise Units Out Now Exceed 100K

    October 2021 OIS Glaucoma Innovation Showcase Monthly Franchise Units Out Now Exceed 100K

  7. Slide 7: Aerie Franchise TRx Performance

    October 2021 OIS Glaucoma Innovation Showcase Aerie Franchise TRx Performance MATTY 6/2020 MATTY 6/2021 % Chg Rhopressa® 373,502 396,309 6% Rocklatan® 136,485 232,538 70% Franchise 509,987 628,847 23% Market 34,768,837 33,857,582 -3% Data source: IQVIA NPA Aerie Franchise prescriptions grew by 119,0

  8. Slide 8: Competitive Market Share

    Competitive Market Share After just 3 years, the Aerie Franchise is 1/3 of the way to overtaking the brand market leader Market share in prescriptions IQVIA data October 2021 OIS Glaucoma Innovation Showcase Brand Leader Market Share 6.1% Launched 2001 Aerie Franchise Market Share 2.0% Launched 2018

  9. Slide 9: Netarsudil Franchise Expansion to the EU

    Netarsudil Franchise Expansion to the EU

  10. Slide 10: Aerie in the EU Glaucoma Market

    October 2021 OIS Glaucoma Innovation Showcase Aerie in the EU Glaucoma Market Sources: IQVIA Midas data at ex-manufacturer price level and Unit-April 2021. *TRx calculated from IQVIA unit data (1 month = 1 TRx) ~$950MM, 98MM Units Rhopressa® (Rhokiinsa®) approved 2019 Rocklatan® (Roclanda®) approved

  11. Slide 11: Netarsudil Franchise Expansion to Japan

    Netarsudil Franchise Expansion to Japan

  12. Slide 12: Approaching the Glaucoma Market in Japan

    October 2021 OIS Glaucoma Innovation Showcase Approaching the Glaucoma Market in Japan Sources: IQVIA Midas data at ex-manufacturer price level and Unit-April 2021. *TRx calculated from IQVIA unit data (1 month = 1 TRx) ~$0.8 B, 60MM TRx Successful Phase 2 topline results for Rhopressa - Nov. 2019 S

  13. Slide 13: Japan Phase 3 Efficacy Study – Netarsudil Demonstrates Superiority to Ripasudil

    October 2021 OIS Glaucoma Innovation Showcase Japan Phase 3 Efficacy Study – Netarsudil Demonstrates Superiority to Ripasudil Data on File * p-value < 0.05 , **p-value < 0.01, ***p-value < 0.001 *** *** ***

  14. Slide 14: Japan Phase 3 Efficacy Study - Safety Summary

    Netarsudil 0.02% was well tolerated Principal ocular adverse event was hyperemia (netarsudil = 54.9%; ripasudil 62.6%) Majority of hyperemia was mild October 2021 OIS Glaucoma Innovation Showcase Japan Phase 3 Efficacy Study - Safety Summary Data on File

  15. Slide 15: From Idea to Global Franchise

    October 2021 OIS Glaucoma Innovation Showcase From VISIONaerie Idea to Global Franchise “The ideal therapeutic goal is the reversal of the basic defect….” David L. Epstein, M.D. (1943-2014)

  16. Slide 16: Thank You!

    Thank You!

Aerie Pharmaceuticals — OIS Glaucoma Innovation Summit 2021 on 6ix